DNOW:NYSEDNOW Inc. Analysis
Data as of 2026-06-14 - not real-time
$14.03
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
DNOW Inc. posted a near‑doubling of revenue year‑over‑year (≈97% growth) to $1.18 B, yet earnings per share fell to a non‑GAAP loss of $0.01, missing consensus by a wide margin. Technical indicators show a neutral trend with the 20‑day SMA ($13.28) just above the 50‑day SMA ($12.91) and a bullish MACD histogram (+0.06), while the RSI sits at 63, suggesting modest momentum but no overbought condition. The stock trades at $14.03, roughly 14% above the DCF‑derived fair value of $7.16, yet its forward P/E of 14.9 is well below the industry average of 30.6, indicating a valuation gap that may be justified by ongoing legal scrutiny and a negative free cash flow position.
The balance sheet shows a high debt‑to‑equity ratio (≈34) and a sizable net debt load of $737 M against $116 M cash, while operating cash flow remains weak. Combined with decreasing volume, a 30‑day volatility of 28% and several pending securities class‑action investigations, the upside potential is tempered by liquidity and legal risks despite the strong top‑line growth.
The balance sheet shows a high debt‑to‑equity ratio (≈34) and a sizable net debt load of $737 M against $116 M cash, while operating cash flow remains weak. Combined with decreasing volume, a 30‑day volatility of 28% and several pending securities class‑action investigations, the upside potential is tempered by liquidity and legal risks despite the strong top‑line growth.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Revenue surge but earnings miss
- Bullish MACD but neutral price trend
- Legal and class‑action exposure
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Sustained high revenue growth
- Forward P/E advantage versus peers
- Potential resolution of legal issues
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Persistent negative free cash flow
- Elevated debt levels
- Industry cyclicality and competitive pressure
Key Metrics & Analysis
Financial Health
Revenue Growth97.50%
Profit Margin-4.52%
P/E Ratio14.9
ROE-9.37%
ROA1.86%
Debt/Equity34.39
P/B Ratio1.2
Op. Cash Flow$76.0M
Free Cash Flow$-723374976
Industry P/E30.6
Technical Analysis
TrendNeutral
RSI63.2
Support$12.72
Resistance$14.16
MA 20$13.28
MA 50$12.91
MA 200$13.77
MACDBullish
VolumeDecreasing
Fear & Greed Index89.86
Valuation
Fair Value$7.16
Target Price$16.00
Upside/Downside14.04%
GradeOvervalued
TypeBlend
Risk Assessment
Beta0.74
Volatility28.16%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.